Update: Availability of Sulfadiazine -- United States
Sulfadiazine is commonly used in combination with
pyrimethamine to treat toxoplasmosis in patients with acquired
immunodeficiency syndrome and in newborns with congenital
infections. After the domestic commercial supplier of sulfadiazine
discontinued marketing the drug in October 1992, CDC temporarily
assumed distribution of sulfadiazine under a Food and Drug
Administration Investigational New Drug protocol. A domestic
commercial source was reestablished in August 1994, and CDC will no
longer distribute sulfadiazine. Additional information is available
from Eon Labs Manufacturing, Inc., 227-15 North Conduit Avenue,
Laurelton, NY 11413; telephone (800) 366-1595 or (718) 276-8607.
Disclaimer
All MMWR HTML versions of articles are electronic conversions from ASCII text into HTML. This conversion may have resulted in character translation or format errors in the HTML version. Users should not rely on this HTML document, but are referred to the electronic PDF version and/or the original MMWR paper copy for the official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.
**Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.
